CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-05-27 | CRAVES FRED B Director | Other disposition | −360,561 | 3,729,141 | ||
| 2020-05-27 | CRAVES FRED B Director | Other disposition | −6,772 | 81,380 | ||
| 2020-05-27 | CRAVES FRED B Director | Other disposition | −44,903 | 72,875 | ||
| 2020-05-27 | BAY CITY CAPITAL LLC 10% owner | Other disposition | −360,561 | 3,729,141 | ||
| 2020-05-27 | BAY CITY CAPITAL LLC 10% owner | Other disposition | −6,772 | 81,380 | ||
| 2020-05-27 | BAY CITY CAPITAL LLC 10% owner | Other disposition | −44,903 | 72,875 | ||
| 2020-03-05 | Lynch Brian Joseph SVP and General Councel | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2020-03-05 | FRIEDMAN PAUL A Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2020-03-05 | Taub Rebecca Pres., R&D, and CMO | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2020-03-05 | Schneebaum Marc R Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2019-12-13 | BAY CITY CAPITAL LLC 10% owner | Sale | −1,174,680 | $105.47 | $123.9M | 4,089,702 |
| 2019-12-13 | BAY CITY CAPITAL LLC 10% owner | Sale | −25,320 | $105.47 | $2.7M | 88,152 |
| 2019-12-13 | CRAVES FRED B Director | Sale | −1,174,680 | $105.47 | $123.9M | 4,089,702 |
| 2019-12-13 | CRAVES FRED B Director | Sale | −25,320 | $105.47 | $2.7M | 88,152 |
| 2019-07-10 | Taub Rebecca President of R&D | Grant or award · Stock Option (Right to Buy) | +8,000 | 8,000 | ||
| 2019-06-27 | Levy Richard S Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-27 | BATE KENNETH Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-27 | Daly James M Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2019-06-27 | CRAVES FRED B Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-27 | Gollust Keith R Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 |
Page 54 of 82 · 1,629 trades